Biogen (BIIB) M&A announcement summary

Deal rationale and strategic fit

• Acquisition expands the commercial growth portfolio with two best-in-class, FDA-approved products (SYFOVRE and EMPAVELI) in immunology, rare diseases, and nephrology, aligning with strategic expansion beyond neuroscience.

• Products address significant unmet needs in geographic atrophy, rare hematology, and kidney diseases, and enhance launch readiness for late-stage kidney disease candidates.

• Provides U.S. infrastructure and nephrology expertise, supporting future launches such as felzartamab.

• The deal fits within a disciplined M&A approach, focusing on assets with near- and long-term growth potential without stretching the balance sheet.

• Supports a broader platform for sustainable growth, complementing existing capabilities in neurology, immunology, and rare diseases.

Financial terms and conditions

• Purchase price is $41 per share, totaling approximately $5.6 billion in cash, with contingent value rights (CVRs) up to $4 per share tied to SYFOVRE global net sales milestones between 2027 and 2031.

• Premium paid is 86% over 90-day VWAP and 35% over the 52-week high, considered in line with comparable transactions.

• Funded through $3.6 billion cash on hand and $2 billion from revolving credit and bank loans, with plans to fully de-lever by end of 2027.

• Revenue from the two products is projected to grow in the mid- to high teens through at least 2028, with accretion to non-GAAP EPS expected from 2027.

• The deal is expected to close in Q2 2026, subject to customary closing conditions and regulatory approvals.

Synergies and expected cost savings

• Combined commercial and medical teams expected to enhance launch execution, patient activation, and market penetration for both products.

• Apellis' nephrology infrastructure and talent provide a foundation for future launches, reducing the need for additional build-out.

• Opportunities identified for cost discipline and potential G&A synergies, especially ahead of felzartamab launch.

• Expected to generate a meaningful increase in non-GAAP EPS CAGR through the end of the decade.

• Transaction is expected to be increasingly accretive starting in 2027.